Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.

@article{Klecker1987PlasmaAC,
  title={Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.},
  author={Raymond W. Klecker and Jerry M. Collins and Robert Yarchoan and Reuben. Thomas and Jean F. Jenkins and Samuel E Broder and Charles E. Myers},
  journal={Clinical pharmacology and therapeutics},
  year={1987},
  volume={41 4},
  pages={407-12}
}
We investigated the clinical pharmacokinetics of azidothymidine (N3TdR) as part of a phase I/II trial in the treatment of acquired immunodeficiency syndrome and related diseases. During the 6-week course of therapy, drug levels in plasma, cerebrospinal fluid, and urine were determined by HLPC. The plasma half-life of N3TdR was 1.1 hour. The total body clearance was 1.3 L/kg/hr. At intravenous doses of 5 mg/kg or oral doses of 10 mg/kg, plasma levels were continuously maintained above the target… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

Clinical pharmacology of zidovudine and other 2′,3′-dideoxynucleoside analogues

The clinical investigator • 1993
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…